

LEAF INSERT

LORASARAN SYRUP 5mg/5ml (LORATADINE SYRUP)

LABEL CLAIM:

Each 5ml Contains :

Loratadine.....5mg

USP Specs.

QUALITATIVE AND QUANTITATIVE COMPOSITION

Ingredients	Quantities / mg/5ml	Quantity / Batch (Kg)	Role of Ingredient
Loratadine (Micronized)	5.000	¹ 3.150	*Active Ingredient is calculated at 100 % potency. Adjust the quantity of API as per actual assay (OAB) if potency varies.
Sugar Pharma Grade	3000.000	1800.00	Sweetening agent
Sodium Benzoate	10.000	6.000	Preservative
Aspartame	0.500	0.300	Sweetening agent
Citric Acid Monohydrate	12.500	7.500	Buffering agent
Glycerin Pure	239.734	143.840	Viscosity enhancer
Hydrochloric Acid 37%	0.00687 (ml)	4.122	Buffering agent
Propylene Glycol	0.735 (ml)	441.000	Co-solvent
Essence of Strawberry 2331	0.0025 (ml)	1.500	Flavouring agent
De-Ionized Water	Q.S. to make 5ml	Q.S. to make 3000 Liter	Vehicle/Solvent

¹Quantity at 100% potency basis with 5% overage for stability.

Excipients with known effects:

Aspartame: Contraindicated in people suffering from phenylketonuria

Propylene Glycol: Eczema

Sucrose (Pharma Grade Sugar): Digestive disorders (in case of intolerance) - Calorie Intake.

Glycerine (also known as Glycerol): Digestive disorders

PHARMACEUTICAL FORM

Syrup

CLINICAL DATA:**THERAPEUTIC INDICATIONS:**

Loratadine 5mg/5ml Syrup is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticarial in adults and children over the age of 2 years.

DOSAGE AND ADMINISTRATION:***Posology***

Adults and children over 12 years of age:

10ml (10mg) of the syrup once daily.

Paediatric population

Children 2 to 12 years of age are dosed by weight:

Body weight more than 30kg: 10ml (10mg) of the syrup once daily;

Body weight 30kg or less: 5ml (5mg) of the syrup once daily.

Efficacy and safety of Loratadine 5mg/5ml Syrup in children under 2 years of age has not been established.

Patients with severe liver impairment:

Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of Loratadine. An initial dose of 10mg every other day is recommended for adults and children weighing more than 30kg, and for children weighing 30kg or less, 5ml (5mg) every other day is recommended.

Patients with severe renal impairment:

No dosage adjustments are required in the elderly or in patients with renal insufficiency.

Elderly:

No dosage adjustments are required in the elderly.

Method of administration

For oral administration.

CONTRA-INDICATIONS:

Loratadine 5mg/5ml Syrup is contraindicated in patients who are hypersensitive to the active substance or to any of the excipients in this formulation

WARNING & PRECAUTION FOR USE:

Loratadine 5mg/5ml Syrup should be administered with caution in patients with severe liver impairment.

This medicinal product contains sucrose; patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

The administration of Loratadine 5mg/5ml Syrup should be discontinued at least 48 hours before skin tests since antihistamines may prevent or reduce otherwise positive reactions to dermal reactivity index.

DRUG INTERACTIONS:

When administered concomitantly with alcohol, Loratadine 5mg/5ml Syrup has no potentiating effects as measured by psychomotor performance studies.

Potential interaction may occur with all known inhibitors of CYP3A4 or CYP2D6 resulting in elevated levels of Loratadine, which may cause an increase in adverse events.

Increase in plasma concentrations of Loratadine has been reported after concomitant use with ketoconazole, erythromycin, and cimetidine in controlled trials, but without clinically significant changes (including electrocardiographic).

Paediatric population

Interaction studies have only been performed in adults.

REPRODUCTION, PREGNANCY AND BREAST-FEEDING:

Pregnancy

A large amount of data on pregnant women (more than 1000 exposed outcomes) indicate no malformative nor feto/neonatal toxicity of Loratadine. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Loratadine 5mg/5ml Syrup during pregnancy.

Breast-feeding

Loratadine is excreted in breast milk, therefore the use of Loratadine is not recommended in breast-feeding women.

Fertility

There are no data available on male and female fertility.

EFFECTS ON ABILITY TO DRIVE AND USE MACHINES:

In clinical trials that assessed driving ability, no impairment occurred in patients receiving Loratadine. However, patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.

UNDESIRABLE EFFECTS:

a. Summary of the safety profile

In clinical trials involving adults and adolescents in a range of indications including AR and CIU, at the recommended dose of 10mg daily, adverse reactions with Loratadine were reported in 2% of patients in excess of those treated with the placebo. The most frequent adverse reactions reported in excess of placebo were somnolence (1.2%), headache (0.6%), increased appetite (0.5%) and insomnia (0.1%).

b. Tabulated list of adverse reactions

The following adverse reactions reported during the post-marketing period are listed in the following table by System Organ Class. Frequencies are defined as very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$), very rare ($< 1/10,000$) and not known (cannot be estimated from the available data).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

System Organ Class	Frequency	Adverse Reaction
Immune system disorders	Very rare	Hypersensitivity reactions(including angioedema and anaphylaxis)
Nervous system disorders	Very rare	Dizziness, Convulsion
Cardiac disorders	Very rare	Tachycardia, palpitation
Gastrointestinal disorders	Very rare	Nausea, dry mouth, gastritis
Hepato-biliary disorders	Very rare	Abnormal hepatic function
Skin and subcutaneous tissue disorders	Very rare	Rash, alopecia
General disorders and administration site conditions	Very rare	Fatigue
Investigations	Not known	Weight increased

c. Paediatric population

In clinical trials in a paediatric population children aged 2 through 12 years, common adverse reactions reported in excess of placebo were headache (2.7%), nervousness (2.3%), and fatigue (1%).

OVERDOSAGE:

Overdosage with Loratadine increased the occurrence of anticholinergic symptoms. Somnolence, tachycardia, and headache have been reported with overdoses.

In the event of overdose, general symptomatic and supportive measures are to be instituted and maintained for as long as necessary. Administration of activated charcoal as a slurry with water may be attempted. Gastric lavage may be considered. Loratadine is not removed by haemodialysis and it is not known if Loratadine is removed by peritoneal dialysis. Medical monitoring of the patient is to be continued after emergency treatment.

PHARMACOLOGICAL PROPERTIES:**Pharmacodynamic properties (with Pharmacotherapeutic class):**

Pharmacotherapeutic group: anti histamines – H₁ antagonist, ATC code: R06A X13.

Loratadine, the active ingredient in Loratadine 5mg/5ml Syrup, is a tricyclic antihistamine with selective, peripheral H₁-receptor activity.

Loratadine has no clinically significant sedative or anticholinergic properties in the majority of the population and when used at the recommended dosage. During long-term treatment there were no clinically significant changes in vital signs, laboratory test values, physical examinations or electrocardiograms.

Loratadine has no significant H₂-receptor activity. It does not inhibit norepinephrine uptake and has practically no influence on cardiovascular function or on intrinsic cardiac pacemaker activity.

Pharmacokinetics:

After oral administration, Loratadine is rapidly and well absorbed and undergoes an extensive first pass metabolism, mainly by CYP3A4 and CYP2D6. The major metabolite-desloratadine (DL)- is pharmacologically active and responsible for a large part of the clinical effect. Loratadine and DL achieve maximum plasma concentrations (T_{max}) between 1-1.5 hours and 1.5-3.7 hours after administration, respectively.

Increase in plasma concentrations of Loratadine has been reported after concomitant use with ketoconazole, erythromycin, and cimetidine in controlled trials, but without clinically significant changes (including electrocardiographic).

Loratadine is highly bound (97% to 99%) and its active metabolite moderately bound (73% to 76%) to plasma proteins.

In healthy subjects, plasma distribution half-lives of Loratadine and its active metabolite are approximately 1 and 2 hours, respectively. The mean elimination half lives in healthy adult subjects were 8.4 hours (range=3 to 20 hours) for Loratadine and 28 hours (range=8.8 to 92 hours for the major active metabolite).

Approximately 40% of the dose is excreted in the urine and 42% in the faeces over a 10-day period and mainly in the form of conjugated metabolites. Approximately 27% of the dose is eliminated in the urine during the first 24 hours. Less than 1% of the active substance is excreted unchanged in active form, as Loratadine or DL.

The bioavailability parameters of Loratadine and of the active metabolite are dose proportional.

The pharmacokinetic profile of Loratadine and its metabolites is comparable in healthy adult volunteers

and in healthy geriatric volunteers.

Concomitant ingestion of food can delay slightly the absorption of Loratadine but without influencing the clinical effect.

In patients with chronic renal impairment, both the AUC and peak plasma levels (C_{max}) increased for Loratadine and its metabolite as compared to the AUCs and peak plasma levels (C_{max}) of patients with normal renal function. The mean elimination half-lives of Loratadine and its metabolite were not significantly different from that observed in normal subjects. Haemodialysis does not have an effect on the pharmacokinetics of Loratadine or its active metabolite in subjects with chronic renal impairment.

In patients with chronic alcoholic liver disease, the AUC and peak plasma levels (C_{max}) of Loratadine were double while the pharmacokinetic profile of the active metabolite was not significantly changed from that in patients with normal liver function. The elimination half-lives for Loratadine and its metabolite were 24 hours and 37 hours, respectively, and increased with increasing severity of liver disease.

Loratadine and its active metabolite are excreted in the breast milk of lactating women.

PHARMACEUTICAL DATA:

Store between 2- 8°C.

Do not freeze.

Protect from light and heat.

PRESENTATION:

Lorasaran Syrup 5mg/5ml is supplied in pack of 60ml Bottle.

MEDICINE ON PRESCRIPTION ONLY:

List 1

MARKETING AUTHORIZATION HOLDER:

SARAN PHARMA

ABIDJAN COCODY 2 PLATEAUX DERRIERE L'EN, RUE J5, LOT 269, SECTION KX
PARCELLE 104, 08 BP 3121 ABIDJAN 08 RCI

MANUFACTURED BY:

Nabiqasim Industries (Pvt.) Ltd.
17/24, Korangi Industrial Area,
Karachi – Pakistan.

DATE OF LAST REVISION:

November 2024